Journal of Innovation in Applied Research (JIAR) is a multidisciplinary, peer-reviewed journal that publishes "innovative and applied research" in the field of Biotechnology, Genetic Engineering, Genetics, Microbiology, Microbial Technology, Computational Biology, Bioinformatics, Pharmaceutical Sciences and biotechnology, Industrial processing, and biotechnology, Agriculture biotechnology and microbiology, Nanotechnology applications in biological and pharmaceutical sciences, Biomedical engineering, Food and Dairy Microbiology, Environmental biotechnology, and Data science applications. JIAR seeks to publish high-quality papers that describe significant and novel findings and advance knowledge in a diversity of scientific fields in the form of original articles, short communications, reviews, case reports, or letters to the editor. JIAR generally accepts 33-35% of papers for publication that is submitted
Manuscripts will be evaluated on the basis that they present new approaches to the investigated topic and are probable to contribute to a research progress or a change in clinical practice. It is understood that all authors listed on a manuscript have agreed to its submission. The signature of the corresponding author on the letter of submission signifies that these conditions have been fulfilled. Received manuscripts will initially be examined by the JIAR editorial office and those thought to have insufficient grounds for publication may be rejected without external evaluation. Manuscripts not prepared in the recommended style described in Research Review Article Template will be sent back to the authors for correction. The authors will be notified with the reference number, once the manuscript has been assigned to an Associate Editor. The assigned manuscripts will be sent to 2-3 independent experts for scientific assessment.
Authors wishing to include figures, tables, or text that have already been published elsewhere will be required to obtain permission from the copyright owner(s) for both the print and online format and to include evidence that such permission has been granted when submitting their papers. Any received material lacking such evidence will be assumed to originate from the authors.
Every effort may be made by the publisher and editorial board to ensure that no inaccurate or misleading data or statements appear in the JIAR. However, they wish to make it clear that the data and opinions appearing in the articles herein are the responsibility of the authors concerned. Accordingly, the publisher and the editorial board accept no liability whatsoever for the consequences of any inaccurate or misleading data or statements, intentional or not.
JIAR seeks to publish experimental and theoretical research results of outstanding significance in the form of original articles, short communications, reviews, case reports, or letters to the editor. Original articles: Articles that represent in-depth research in various scientific disciplines. Short communications: Should be complete manuscripts of significant importance. However, their length and/or depth do not justify a full-length paper. The total number of figures should not exceed 6 whereas a total number of tables should not exceed 2. The number of words should be = 3,000 Review articles: Should normally comprise less than 10,000 words; contain unstructured abstract and includes up-to-date references. Meta-analyses are considered as reviews. Special attention will be paid to the teaching value of review papers. Mini-reviews: These are reviews of important and recent topics that are presented in a concise and well-focused manner. The number of words is limited to 5,000 words. Case reports: A detailed report of the symptoms, signs, diagnosis, treatment, and follow-up of an individual patient (i.e., clinically important information on common and rare conditions). Letter to the editor for comments on recently published articles. Special reports: Papers may be accepted on the basis that they provide a systematic, critical, and up-to-date overview of literature pertaining to research or clinical topics.
The manuscript should be compiled in the following order: The manuscript should be compiled in the following order: Novelty Statement, List of five referees with their full contact information, Title, Authors & Affiliations, Abstract, Keywords, Introduction, Experimental, Results, and Discussion, Conclusion, Acknowledgments, References and Notes, Legends, Tables, Figures, and Schemes.
Novelty Statement: A statement of novelty should be provided in not more than 100 words giving a brief description of the original research conducted in the submitted manuscript.
Title: The title should be brief, specific, and rich in informative words; it should not contain any literature references or compound numbers.
Authors and Affiliations: Where possible, supply given names, middle initials, and family names for complete identification. Use superscript lowercase letters to indicate different addresses, which should be as detailed as possible and must include the country name. The corresponding author should be indicated with an asterisk, and contact details (email, fax) should be placed in a footnote. Information relating to other authors (e.g., present addresses) should be placed in footnotes indicated by the appropriate symbols (overleaf).
Abstracts: Authors must include a short abstract of approx 100 - 300 words that states briefly the purpose of the research, the principal results, and major conclusions. References and compound numbers should not be mentioned in the abstract unless full details are given.
Keywords: Authors should provide at least 4 keywords that define the major areas of the manuscript's focus of research. These keywords will be used for indexing purpose.
Introduction
The author(s) should endeavor to define the significance of the work and the justification for its publication. Any background discussion should be brief and restricted to relevant material.
Material and methods (Experimental or Methodology)
Authors should be as concise as possible in experimental descriptions. The experimental section must contain all of the information necessary to assure reproducibility. Previously published methods should be indicated by a reference and only relevant modifications should be described. All vendor details, including company, city, and country, should be mentioned for chemicals, reagents, strains, etc. For statistical analysis, please state the appropriate test(s) in addition to a hypothesized p-value or significant level (for example 0.05).
Results
The study results should be clear and concise. Restrict the use of tables and figures to depict data that is essential to the message and interpretation of the study. Do not duplicate data in both figures and tables. The results should be presented in a logical sequence in the text, tables and illustrations.
Discussion
This should explore the significance of the results of the work, not repeat them. Include in the discussion the implications of the findings and their limitations, how the findings fit into the context of other relevant work, and directions for future research.
Conclusion(s)
The main conclusion(s) of the study should be presented in a short conclusion statement that can stand alone and be linked with the goals of the study. State new hypotheses when warranted.
Include recommendations when appropriate. Unqualified statements and conclusions not completely supported by the obtained data should be avoided.
Acknowledgment: An acknowledgment section may be included. It should be placed after the manuscript text and before the references.
Abbreviations (if any): Standard ACS abbreviations should be used throughout the manuscript and are employed without periods. The preferred forms for some of the more commonly used abbreviations are mp, bp, μC, K, min, h, mL, μL, g, mg, μg, cm, mm, nm, mol, mmol, μmol, M, mM, μM, ppm, HPLC, TLC, GC, 13C NMR, 1H NMR, GCMS, HRMS, FABHRMS, UV, FTIR, EPR, ESR, DNase, IV, XRD, EDX, XPS, ED50, ID50, IC50, LD50, im, ip, iv, mRNA, RNase, rRNA, tRNA, cpm, Ci, dpm, Vmax, Km, k, t1/2. All nonstandard abbreviations should be defined following the first use of the abbreviation.
Conflict of Interest: The author should declare the conflict of interest.
References Citation in text: (APA Format)
All citations in the text should refer to:
1. Single author: the author's name (without initials, unless there is ambiguity) and the year of publication (Smith, 2003)
2. Two authors: both authors' names and the year of publication (Smith & Jones, 2004)
3. Three, four, or five authors: all authors' names and year of publication (Smith, Jones, & Brown, 2005). For all subsequent citations of this work use et al. (Smith et al., 2005).
4. Six or more authors: first author's name followed by et al. and the year of publication (Black et al., 2007). Citations may be made directly or parenthetically. Groups of references should be listed first alphabetically, then chronologically, e.g., (Allan, 1996a, b, 1999; Allan & Jones, 1995; Allen et al., 1994). Kramer et al. (2000) have recently shown..."